Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
Recruiting
99 years or below
All
Phase 1
6 participants needed
1 Location

Brief description of study

You are being invited to participate in a research study because you have Bronchiolitis Obliterans Syndrome. Bronchiolitis Obliterans Syndrome (BOS) is a long term (chronic) rejection process that can occur in the transplanted lungs.  Itacitinib works by blocking your body from producing substances called cytokines. Cytokines can cause inflammation that may contribute to your BOS. This is an open-label Study, which means that both you and your Study Doctor will know what Study Drug you are receiving.
 
The Study has 2 phases, or parts.  The Study Doctor will tell you whether you will be in Phase 1 or Phase 2 of the Study, and which cohort (treatment group) you might be in if you are in Phase 1.
 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Bronchiolitis Obliterans Syndrome
  • Age: 99 years or below
  • Gender: All


Updated on 19 Feb 2024. Study ID: 834433

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.